Introduction {#sec1}
============

The 2019 novel corona virus (COVID-19) has resulted in a pandemic that has overwhelmed many health systems across the world.[@bib1] As of June 21,^st^ 2020, there have been over two million cases in the United States with over 200,000 cases in New York City (NYC) alone.[@bib2] NYC was the epicenter of the pandemic and had more COVID-19 cases than many other countries in the world.[@bib3] Mount Sinai Health System is in the heart of NYC and as a result has experienced a high volume of COVID-19 patients.

COVID-19 has a wide range of recognized presentations from asymptomatic carriers to upper respiratory symptoms. In severe cases, the virus can result in Acute Respiratory Distress Syndrome (ARDS), sepsis, and death[@bib4]. There is also increasing evidence that patients with COVID-19 infection appear to have a virus-induced hypercoagulability which results in significant thrombotic events[@bib5]. Initial reports showed that anticoagulation may result in decreased mortality in patients with COVID-19[@bib6] presumably by reducing pulmonary embolism and thrombotic complications.[@bib7] The mechanism of thrombosis is still incompletely elucidated but is thought to involve dysregulation of the clotting cascade as well as endothelial dysfunction[@bib8] and endotheliitis.[@bib9]

At the start of the pandemic, there was a noticeable increase in the number of vascular surgery consultations at our institution for acute large vessel thrombosis in both the arterial and venous circulation. We describe our experiences with laboratory confirmed COVID-19 patients who experienced an acute vascular event. Managing acute thrombotic events from the novel virus presents unprecedented challenges during the COVID-19 pandemic. Our study highlights the thrombotic complications of COVID-19, unique management of these patients, and discusses the role of anticoagulation in patients diagnosed with COVID-19.

Methods {#sec2}
=======

Data Source and Selection of Patients {#sec2.1}
-------------------------------------

Data was prospectively collected and maintained for all vascular surgery consultations in the Mount Sinai Health System. Data was collected from March 1^st^, 2020 to April 15^th^, 2020. Patients with laboratory-confirmed COVID-19 infections using Polymerase Chain Reaction (PCR) testing were selected. Patients who tested negative for COVID-19 despite respiratory symptoms were excluded. Any patient with chronic respiratory symptoms without an acute component occurring within two weeks were excluded. Mild COVID-19 infection was defined as a hospitalized patient with SpO~2~ greater than 94% and no radiographic evidence of pneumonia. Moderate COVID-19 infection was defined as hospitalized patients with hypoxia (SpO~2~ less than or equal to 94%) or radiographic evidence of pneumonia. Severe COVID-19 infection was defined as patient requiring more than nasal cannula to maintain oxygen saturation or mechanical ventilation. These definitions are modified from established classifications.[@bib10] ^,^ [@bib11]Thrombotic events were subdivided into arterial and venous classifications.

Statistical Analysis {#sec2.2}
--------------------

Patients were analyzed on the basis of demographics, comorbidities, home medications, laboratory markers, and outcomes. The primary postoperative outcome of interest was mortality. The secondary postoperative outcomes of interest were primary patency and morbidity. To assess for significance in patient demographics, comorbidities, home medications, laboratory markers, and outcomes, univariate analysis was performed using Pearson χ2 and Fisher exact tests for categorical variables and Student t-test for continuous variables. P value of \< .05 was considered to be statistically significant. All analyses were performed with SAS 9.4 (Cary, NC). IRB approval was obtained for this study.

Results {#sec3}
=======

The daily number of hospitalized patients with COVID-19 in the health system during this study period ranged between 900 to 2000 patients. From these hospitalized patients, there were over 30 vascular consultations in COVID-19 positive of which 21 patients with acute thrombotic events met our inclusion and exclusion criteria ([Table 1](#tbl1){ref-type="table"} ). 14 patients (66.7%) were admitted for a thrombotic event and found to have COVID-19. The remaining 7 patients were admitted initially for COVID-19 and subsequently developed a thrombotic event. The majority of cases were acute arterial events (76.2%) while the remainder were venous cases (23.8%). The average age of all patients was 64.6 years-old and 52.4% were male. The majority of patients were either Caucasian (28.6%), African-American (28.6%), or Hispanic (28.6%). No Asian patients presented with arterial events (0% vs. 60%, p=.008). There was a trend toward more venous events in women (60% vs. 40%, p=0.70). The majority of patients were on an antiplatelet (76.2%) or anticoagulant (19.1%) agent prior to admission. 23.8% of patients were on clopidogrel prior to admission and 52.4% were on aspirin. 19.1% were on anticoagulation prior to admission. The indications for preoperative anticoagulation include atrial fibrillation and history of deep vein thrombosis. All patients who underwent revascularization were started on anticoagulation preoperatively. Of the four mortalities, two of these patients were on subcutaneous heparin at 5000U q12 hours after surgery. One was on enoxaparin 40 mg daily for 3 days. The final patient was on apixaban at home.Table 1Patient demographics and preoperative medicationsFactorAll Patients (%)Arterial Cases (%)Venous Cases (%)P-valueTotal \# of patients21 (100%)16 (76.2%)5 (23.8%)\--Age64.663.378.00.08Female11 (52.4%)8 (50%)3 (60%)0.70**Ethnicity**Caucasian6 (28.6%)6 (37.5%)0 (0%)0.11Hispanic6 (28.6%)6 (37.5%)0 (0%)0.11African American6 (28.6%)4 (25.0%)2 (40.0%)0.52Asian3 (14.3%)0 (0%)3 (60.0%)\<0.01**Medications prior to admission**Plavix5 (23.8%)5 (31.3%)0 (0%)0.15Aspirin11 (52.4%)10 (62.5%)1 (20.0%)0.10ACE inhibitor or ARB7 (33.3%)5 (31.3%)2 (40.0%)0.72Anticoagulant4 (19.1%)3 (18.8%)1 (20.0%)0.95

As seen in [Table 2](#tbl2){ref-type="table"} , the most prevalent comorbidity in the group was hypertension (81.0 %). Other common presenting medical problems included hyperlipidemia (66.7%), diabetes mellitus (47.5%), acute renal failure (47.6%), and current or former smokers (81.0%). There were no significant differences in comorbidities between arterial and venous cases. Average body mass index (BMI) was high at 31.5. The majority of patients had either mild (38.1%) or moderate (47.6%) COVID-19 infections.Table 2Medical comorbidities and COVID-19 severityMedical comorbiditiesAll Patients (%)Arterial Cases (%)Venous Cases (%)P-valueHypertension17 (81.0%)14 (87.5%)3 (60.0%)0.17Hyperlipidemia14 (66.7%)12 (75.0%)2 (40.0%)0.14Peripheral Vascular Disease6 (28.6%)6(37.5%)0.11Diabetes Mellitus10 (47.6%)9 (56.3%)1 (20.0%)0.16Acute Kidney Injury10 (47.6%)7 (43.8%)3 (60.0%)0.53Chronic Kidney Injury2 (9.5%)2 (12.5%)0 (0%)0.41ESRD on HD1 (4.8%)1 (6.3%)0 (0%)0.57Coronary Artery Disease (CAD)6 (28.6%)5 (31.3%)1 (20%)0.63Congestive Heart Failure (CHF)4 (19.1%)3 (18.8%)1 (20%)0.95CVA4 (19.1%)3 (18.8%)1 (20%)0.95Body Mass Index (BMI)31.533.626.050.54COPD2 (9.5%)2 (12.3%)0 (0%)0.41**Smoking Status**Never Smoker10 (47.6%)6 (37.5%)4 (80%)0.10Former Smoker7 (33.3%)6 (37.5%)1 (20%)0.47Current Smoker2 (9.5%)2 (12.5%)0 (0%)0.41**COVID-19 Severity**Mild8 (38.1%)7 (43.8%)1 (20%)0.34Moderate10 (47.6%)7 (43.8%)3 (60%)0.53Severe3 (14.3%)2 (12.5%)1 (20%)0.38

Several laboratory values were markedly abnormal in both arterial and venous cases, including an elevated neutrophil: lymphocyte ratio (8.8), d-dimer (4.9 mcg/mL), fibrinogen (634.1 mg/dL), ferritin (929.1 ng/mL), and lactate dehydrogenase (516.6 U/L) ([Table 3](#tbl3){ref-type="table"} ). Procalcitonin levels differed significantly between the arterial and venous group (19.34 ng/ml vs. 0.08 ng/mL, p\<.01). Of note, 85.7% of patients presented with lymphopenia on admission.Table 3Preoperative Laboratory Markers and ImagingLaboratory MarkerAll PatientsArterial CasesVenous Casesp-valueHematocrit (%)38.838.440.10.49White Blood Count (WBC) (10^3^/uL)12.413.110.40.90Platelets (10^3^/uL)3313672170.27Neutrophil:Lymphocyte Ratio8.810.46.50.18INR1.21.251.10.27PTT (seconds)35.736.034.80.79Creatinine (mg/dL)1.51.41.60.88D-Dimer (UG/mL)4.94.07.20.32Fibrinogen (mg/dL)634.1654.3593.70.45Procalcitonin (ng/mL)14.119.30.08\<.01Ferritin (ng/mL)929.11004.5627.30.15Lactate Dehydrogenase (LDH) U/L516.6558.9403.70.68Erythrocyte Sedimentation Rate (ESR)92.292.9870.93C-Reactive Protein (CRP) (MG/L)76.782.756.90.20Lactate (mmol/L)1.61.70.80.30Troponin (ng/mL)0.050.060.040.55**Preoperative Imaging**Arterial or Venous Duplex5 (23.8%)4 (25%)1 (20%)0.82Preoperative Computed Tomography Angiography (CTA)7 (33.3%)4 (25%)3 (60%)0.15

The most frequently involved arterial segment was the femoropopliteal region (38.1%) ([Table 4](#tbl4){ref-type="table"} ). Two patients underwent thrombolysis ([Table 4](#tbl4){ref-type="table"}). One patient underwent thrombolysis for radial and ulnar artery thrombosis; the second patient underwent catheter-directed thrombolysis on POD 0 and then embolectomy the subsequent day. Seven patients (33.3%) were managed conservatively and two patients (9.5%) underwent primary amputation ([Table 5](#tbl5){ref-type="table"} ). The four patients that required general anesthesia were intubated for the operation. The remaining cases underwent revascularization with either a percutaneous angiogram (25.0%) or open surgical embolectomy (23.8%). The majority of arterial interventions had a postoperative complication (53.9%) versus a 0% complication in the venous interventions ([Table 5](#tbl5){ref-type="table"}). Postoperative complications included pneumonia (41.7%), shock (41.7%), acute renal failure (33.3%), cardiac arrest (33.3%), and myocardial infarction (16.7%) in the arterial group. The in-hospital primary patency was 100% and major amputation rate was 0% during the duration of this study. The mortality was 33.3% in the arterial group and 0% in the venous group. Of the 4 patients who expired, the cause of death was hypoxic respiratory failure leading to cardiac arrest in three patients and septic shock in one patient. 3 out of 4 patients who expired were on anticoagulation. Hospital length of stay was 8.33 days for all patients.Table 4Anatomic and Procedural Information. Parenthesis denotes Rutherford classification.Anatomic LocationAll Patients (%)\-\-\--Aortoiliac or Inferior vena cava1 (4.76%)\-\-\--Iliofemoral3 (18.75%)\-\-\--Femoropopliteal8 (38.10%)\-\-\--Infrageniculate2 (9.52%)\-\-\--Upper Extremity10 (47.62%)\-\-\--**Anatomic Location (Rutherford classification)InterventionPostoperative AnticoagulationOutcome**Upper extremity deep vein thrombosisPalliative careN/ADeceasedLower extremity deep vein thrombosisConservativeApixibanAliveCommon femoral artery thrombosis (3)Left above knee guillotine amputationEnoxaparinDeceasedPeroneal artery thrombosis (2a)Angiogram with peroneal angioplastyApixabanDeceasedRadial artery thrombosis (2a)ConservativeEnoxaparinAliveSuperficial Femoral Artery Thrombosis (2a)Thrombolysis (POD 0); open surgical embolectomy (POD 1)WarfarinAlivePosterior Tibial (PT) Artery Thrombosis\
(2a)balloon angioplasty and stenting of the PTApixabanDeceasedUnknownBelow knee AmputationApixabanAliveSuperficial Femoral Artery Thrombosis (1)ConservativeRivaroxabanAliveIliofemoral DVTPercutaneous mechanical thrombectomywith venoplasty and stentingApixabanAliveSuperficial Femoral Artery Thrombosis with reconstitution of the peroneal artery (2b)Percutaneous thrombectomy with thrombolysisApixabanAliveCommon iliac artery, popliteal artery, and anterior tibial artery thrombosis (2b)Surgical Embolectomy with fasciotomiesIntravenous unfractionated heparinAliveUnknown (3)Above knee amputationApixabanDeceasedRadial and ulnar artery thrombus (unknown)ConservativeIntravenous unfractionated heparin (admitted)DeceasedSuperficial Femoral and Popliteal Artery Thrombosis (3)Below knee amputationIntravenous unfractionated heparinAliveLower extremity deep vein thrombosisIVC filterRivaroxaban (on discharge)AliveAxillary artery occlusion (unknown)Surgical EmbolectomyEnoxaparinAlivePopliteal and tibial artery thrombosis (2b)Surgical EmbolectomyApixabanAliveRadial and Ulnar artery thrombosis (2b)Angiogram with thrombolysisEnoxaparinAliveExternal Iliac Artery Occlusion (unknown)Surgical EmbolectomyRivaroxabanAliveIliofemoral and femoropopliteal deep vein thrombosisConservativeIntravenous unfractionated heparinAliveTable 5Perioperative Information and ComplicationsProcedure TypeAll Patients (%)Arterial Cases (%)Venous Cases (%)P-ValuePercutaneous/Angiogram4 (25.0%)2 (40.0%)6 (28.6%)0.52Open Surgery or Bypass5 (23.8%)5 (31.3%)0 (0%)0.15Primary Major Amputation2 (9.5%)2 (12.5%)0 (0%)0.41Conservative or Palliative7 (33.3%)4 (25.0%)3 (60.0%)0.15**Type of Anesthesia**General4 (19.1%)4 (25.0%)0 (0%)0.21MAC8 (38.1%)6 (37.5%)2 (40.0%)0.92**Complications**Any Postoperative Complication8 (57.1%)8 (66.7%)0 (0%)0.078Deep Vein Thrombosis0 (0%)0 (0%)0 (0%)0.98Pulmonary Embolism0 (0%)0 (0%)0 (0%)0.98Myocardial Infarction (MI)2 (14.3%)2 (16.7%)0 (0%)0.53Pneumonia6 (42.9%)5 (41.7%)0 (0%)0.83Stroke1 (7.1%)1 (8.3%)0 (0%)0.67Acute Renal Failure4 (28.6%)4 (33.3%)0 (0%)0.33Acute Liver Injury2 (14.3%)2 (16.7%)0 (0%)0.53Intubation/Reintubation4 (28.6%)4 (33.3%)0 (0%)0.33Shock/Sepsis5 (35.7%)5 (41.7%)0 (0%)0.25Cardiac Arrest4 (28.6%)4 (33.3%)0 (0%)0.33Death4 (28.6%)4 (33.3%)0 (0%)0.33Major Amputation0 (0%)0 (0%)0 (0%)0.98Primary Patency14 (100%)12 (100%)2 (100%)0.98Reintervention2 (14.3%)2 (16.7%)0 (0%)0.53Hospital Length of Stay8.38.95.50.47

Risk factors that were more prevalent in patients with COVID-19 who expired include general anesthesia (50.0% vs 18.18% p=0.22) and AKI on admission (75.0% v. 18.2%, p=0.04). All mortalities occurred in females (100% v. 45.5%, p=0.057) and patients over 55 (100% v. 45.5%, p=0.057) ([Table 6](#tbl6){ref-type="table"} ).Table 6Factors associated with postoperative mortality after univariate analysisFactorp-valueFemale0.057Age \>550.057General anesthesia0.217AKI on admission0.039

Discussion {#sec4}
==========

Given our findings, patients with COVID-19 infection have a viral induced hypercoagulability and are at high risk for arterial and venous thromboembolism. There were over 30 thrombotic complications during our study period. In comparison, during the 45-day period preceding this study, there were only 9 interventions for acute thrombotic events of which 7 were arterial and 2 were venous cases. This translates to over a 3-fold increase in the rate of thrombotic events. There is increasing evidence that patients with COVID-19 are prone to thrombotic complications[@bib12]. Some authors postulate that these events can potentially be explained by disseminated intravascular coagulation (DIC) which is thought to contribute to thrombotic complications in critically-ill septic COVID-19 patients[@bib13]. However, in 38.1% of our thrombotic cases, patients only had mild COVID-19 infections and no evidence of DIC. Interestingly, the initial presentation in five cases (23.8%) was an acute thrombotic event without upper respiratory symptoms. These patients were incidentally found to have laboratory confirmed COVID-19 infection. Thus, we suspect there may be another underlying mechanism for hypercoagulability in these patients which may not correlate to severity of COVID-19 infection. It has been suggested that the severity of the inflammatory response correlates with the severity of COVID-19 disease.[@bib14] However, since we observed a majority of thrombotic events in patients with mild COVID-19 symptoms, this suggests that the hypercoagulability risk of COVID-19 may not be due to the degree of inflammatory response alone. There is increasing evidence that there is a viral-induced endotheliitis and this may contribute to the hypercoaguability.[@bib15]

We identified several prevalent comorbidities in patients with thrombotic events, including hypertension, hyperlipidemia, diabetes mellitus, and acute renal failure. These comorbidities are much more prevalent in our cohort when compared to other reported cases of COVID-19 in the literature and may be significant risk factors for thrombotic events[@bib16]. Interestingly, all patients who expired in our cohort were female and over 55 years of age. Both female gender and older age have been shown to be a poor prognostic factor following vascular surgery interventions**.** [@bib17] Thus, both risk factors are also likely poor prognostic factors for ischemic events following COVID-19 infection.

There are numerous studies that show COVID-19 patients have multiple laboratory abnormalities, including decreased antithrombin levels, elevated d-dimer, decreased PTT elevated fibrin-degradation products, and increased fibrinogen[@bib10]. In our patients, there were several markedly elevated laboratory values, including d-dimer, fibrinogen, and LDH. Although more data is needed, perhaps elevated d-dimer and fibrinogen can be utilized as a marker for patients who will be at high risk for thrombotic complications from COVID-19. Another notable laboratory finding was a very high neutrophil:lymphocyte (NLR) ratio of 8.83. Other studies have correlated a high NLR as a predictor for progression of COVID-19 infection[@bib18]. In line with this, our cohort had a high postoperative sepsis and mortality rate of 35.7% and 28.6%, respectively. This may be due to progression of COVID-19 infection. It is hypothesized that the virus acts on T lymphocytes and downstream sequalae may be an important factor in clot formation and propagation[@bib10]. Furthermore, there were elevated levels of procalcitonin only in patients with arterial thrombosis but not venous events. Studies have shown an association between procalcitonin and COVID-19 disease severity[@bib19] ^,^ [@bib20] but the mechanism of this remains unclear.

The acute vascular presentations of COVID-19 bring up several unique considerations and important management strategies. First, all patients during the pandemic who present with thrombotic events should undergo COVID-19 testing as this may be a major risk factor. This is particularly important in patients who are young or who have no significant risk factors for thrombosis. Additionally, based on our experience and current available data, we recommend that anticoagulation should strongly be considered in hospitalized patients with COVID-19 infections and high-risk patients in the outpatient setting. Recent studies demonstrate benefits of anticoagulation in patients with COVID-19 sepsis[@bib12]. Most studies evaluating anticoagulation for COVID-19 patients have utilized heparin-based therapy[@bib19]. Heparin-based therapies are currently recommended as they (1) bind strongly to the COVID-19 spike proteins[@bib20] ^,^ [@bib21] and (2) downregulate elements of the inflammatory process, including IL-6[@bib22]

The decision to intervene on patients with COVID-19 and an acute thrombotic event must carefully be evaluated. The threshold to intervene will depend on the respiratory status, severity of ischemia, and overall prognosis. Although varying rates are reported in the literature, the risk of mortality following COVID-19 infections is approximately 3.7%[@bib23]. In our cohort, the mortality rate for arterial thrombosis was high at 33.3% despite only a minority of patients having severe COVID-19 infections at time of presentation. All mortalities and complications occurred following arterial thrombosis despite no significant difference in comorbidities suggesting venous thrombosis has a much better prognosis. The majority of arterial cases also had significant complications, including pneumonia, intubation or reintubation, myocardial infarction, and acute renal failure. However, the short-term primary patency was 100% with no reoperations for major amputation. Thus, although acute arterial thrombotic events are a poor prognostic marker for complications and mortality, short-term patency and limb salvage rates remain high**.** The risk factors we identified for mortality which include age over 55 years, preoperative AKI, and female gender should also be considered when determining optimal management. Additionally, there may be a reduction in mortality if local or regional anesthesia is used to avoid intubation. In early reports, the mortality rate of patients with COVID-19 who require intubation exceeds 80%[@bib24] ^,^ [@bib17]. 19.1% of patients in our study underwent general anesthesia. We found a much higher mortality rate (50.0% vs 18.1%, p =0.22) in patients who required intubation. These patients were intubated for the procedure in the operating room and thus avoiding general anesthesia in these patients may be critical to reducing perioperative mortality.

There are several limitations to our study. First, the number of acute thrombotic events at our institution is likely higher than what is reported in this study. In part, this may be from false negative tests with nasal swabs which was routinely used in our institution during this time period. The rate of false negatives from PCR COVID-19 testing can exceed 30%[@bib25]. Thus, patients with symptoms consistent with COVID-19 but negative testing were excluded from the study. Additionally, patient data was obtained through vascular surgery consultation in the health system. There is likely a significant portion of patients with thrombotic events which was managed by the primary team without vascular surgery consultation, particularly in the case of deep vein thromboses. Patients with COVID-19 who developed thrombotic complications may have been critically-ill and only a palliative route was pursued by the primary team. Furthermore, although there is no control group, there was a marked increased rate of acute ischemic and venous thrombotic consultations at the start of the pandemic. The majority of these thrombotic events occurred in COVID-19 patients who were comparatively younger and without significant risk factors. The increased rates of thrombotic events also emphasize the importance of having a vascular surgeon and interventionalist readily available during the pandemic. Finally, the incidence of thrombotic events in this study may be under-reported as patients opted to stay at home and had a delayed presentation after the study period.

Conclusion {#sec5}
==========

COVID-19 infection typically presents with respiratory symptoms such as fever, cough, or shortness of breath. However, there is increasing evidence of a viral induced hypercoagulability in COVID-19 infections which may not correlate with severity of infection. We describe our experience in the epicenter of the pandemic of over 20 patients who experienced major thrombotic events from COVID-19. Our cohort highlights the need for increased awareness of vascular manifestations of COVID-19 and the important role of anticoagulation in these patients. More data is urgently needed to optimize treatments and prevent further vascular complications of COVID-19 infections.
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ARTICLE HIGHLIGHTS

**Type of Research:** Single-center retrospective cohort study

**Key Findings:** Acute arterial (76.2%) and venous (23.8%) thrombotic complications of the peripheral circulation occurred in 21 patients with COVID-19 disease. Operative intervention included percutaneous angiogram in 25.0% of patients and open surgical embolectomy in 23.8%. The majority of arterial interventions had a postoperative complication (53.9%) versus a 0% complication in venous interventions. AKI on admission and general anesthesia were independent risk factors of mortalities (p\<0.05).

**Take home Message:** Our cohort highlights the need for increased awareness of vascular manifestations of COVID-19 and outcomes of operative intervention and anticoagulation in these patients.

Acute venous (23.8%) or arterial (76.2%) thrombosis was seen in 21 COVID-19 positive patients. The majority of these patients had mild to moderate COVID-19 disease and no signs of disseminated intravascular coagulation (DIC). Operative intervention for limb salvage appears to be successful but with increased perioperative risks..
